Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

Background: The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. However, the impact of these modulators on gastrointestinal (GI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mainz, Jochen G., Zagoya, Carlos, Polte, Louise, Naehrlich, Lutz, Sasse, Lenny, Eickmeier, Olaf, Smaczny, Christina, Barucha, Anton, Bechinger, Lilith, Duckstein, Franziska, Kurzidim, Ludwik, Eschenhagen, Patience, Caley, Laura, Peckham, Daniel, Schwarz, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203829/
https://www.ncbi.nlm.nih.gov/pubmed/35721187
http://dx.doi.org/10.3389/fphar.2022.877118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203829/
https://www.ncbi.nlm.nih.gov/pubmed/35721187
http://dx.doi.org/10.3389/fphar.2022.877118

Ejemplares similares